Transposon Therapeutics

Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformational therapies for neurodegenerative and aging-related diseases driven by LINE-1 retrotransposon activity. Its lead asset, TPN-101 (censavudine), is a potent oral inhibitor of LINE-1 reverse transcriptase in late-stage development for progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) / frontotemporal dementia (FTD), and Alzheimer's disease. The pipeline also includes follow-on novel nucleoside reverse transcriptase inhibitors (NRTIs) and Protein Kinase R inhibitors (PKRi) targeting pathways activated by LINE-1 and implicated in cognitive impairment. Surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network; enrichment found a corporate marketing website only and no public API, developer, or machine-readable surface.

Transposon Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Neurodegeneration, and Clinical Stage.

Transposon Therapeutics’ developer surface includes support, product news, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

14.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsNeurodegenerationClinical StageDrug DevelopmentLife SciencesNeuroscience

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 14.6/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/transposon-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

News

News

Source (apis.yml)

aid: transposon-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/transposon-therapeutics.png
name: Transposon Therapeutics
description: Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformational therapies
  for neurodegenerative and aging-related diseases driven by LINE-1 retrotransposon activity. Its lead asset, TPN-101 (censavudine),
  is a potent oral inhibitor of LINE-1 reverse transcriptase in late-stage development for progressive supranuclear palsy
  (PSP), amyotrophic lateral sclerosis (ALS) / frontotemporal dementia (FTD), and Alzheimer's disease. The pipeline also includes
  follow-on novel nucleoside reverse transcriptase inhibitors (NRTIs) and Protein Kinase R inhibitors (PKRi) targeting pathways
  activated by LINE-1 and implicated in cognitive impairment. Surfaced as a portfolio company of Canaan Partners and added
  to the API Evangelist network; enrichment found a corporate marketing website only and no public API, developer, or machine-readable
  surface.
url: https://raw.githubusercontent.com/api-evangelist/transposon-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Neurodegeneration
- Clinical Stage
- Drug Development
- Life Sciences
- Neuroscience
apis: []
common:
- type: DomainSecurity
  url: security/transposon-therapeutics-domain-security.yml
- type: Website
  url: https://transposonrx.com
- type: PrivacyPolicy
  url: https://transposonrx.com/privacy.html
- type: TermsOfService
  url: https://transposonrx.com/termsofuse.html
- type: Support
  url: https://transposonrx.com/connect.html
- type: News
  url: https://transposonrx.com/news.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1